Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02952898 · ClinicalTrials.gov registry record · Phase 3
Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses
A Phase 3 study, sponsored by Balmoral Medical company.
- Completed
- Registry status
- Phase 3
- Development phase
- 665
- Enrollment target
NCT02952898: Completed Phase 3 study, sponsored by Balmoral Medical company.
NCT02952898 is a Phase 3 study that has completed, run by Balmoral Medical company. The registered enrollment target is 665 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02952898, a Phase 3 study, has completed, sponsored by Balmoral Medical company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 665 participants
- Enrollment target
Study Summary
This research study is being done to compare the safety and effectiveness of GDC 695 (test drug) against the currently marketed reference drug (diclofenac sodium gel, 3%) and to establish that these two drugs work better than placebo in the treatment of actinic keratosis.
Primary Outcome
Complete Clearance was defined as 100% clearance of all Actinic Keratosis (AK) lesions (having a count of zero AKs) in the treatment area (face or bald scalp) at the Day 90 visit (30 Days Post Treatment).
Interventions
- DRUG Vehicle gel
- DRUG GDC 695
- DRUG Diclofenac Sodium Gel, 3%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 665 participants |
| Start Date | 2016-10-27 |
| Est. Completion | 2017-09-06 |
| Phase | Phase 3 |
What the finished NCT02952898 record still lists
NCT02952898 is an interventional study that assigns participants to a tested intervention. The registered 665 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (14% lower).
The record links to 0 conditions, and to 3 interventions - of which Vehicle gel is the first listed.
NCT02952898 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02952898 about?
NCT02952898 is a clinical study titled "Study Comparing GDC 695 and Diclofenac Sodium Gel, 3% in Subjects With Actinic Keratoses". This research study is being done to compare the safety and effectiveness of GDC 695 (test drug) against the currently marketed reference drug (diclofenac sodium gel, 3%) and to establish that these two drugs work better than placebo in the treatment of actinic keratosis.
What is the current status of trial NCT02952898?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 665 participants. The study started on 2016-10-27. Estimated completion is 2017-09-06.
What interventions are being tested in trial NCT02952898?
The interventions under investigation include: Vehicle gel (DRUG), GDC 695 (DRUG), Diclofenac Sodium Gel, 3% (DRUG).
Who is sponsoring clinical trial NCT02952898?
This trial is sponsored by Balmoral Medical company, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02952898's enrollment target sits among peer trials
665 552nd of 2000 higher than 1,448 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04064060 · 665 participants · Phase 3
A Study to Evaluate Long-term Safety in Participants Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials
- NCT06328647 · 666 participants · NA
Quantra Point-of-Care Hemostasis Monitoring
- NCT06981078 · 666 participants · Phase 2
A Study to Assess the Efficacy and Safety of Verekitug in Participants With COPD
- NCT06607341 · 664 participants · NA
Community Engagement Alliance Against Disparities
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI